In the analysis of these hemodialysis patients, the investigators concluded that pegloticase treatment for refractory gout was safe and effective. Erythropoiesis-stimulating agent (ESA) use was similar before and after pegloticase treatment, but the investigators noticed a significantly lower monthly dose requirement after pegloticase treatment. The monthly ESA dose (n=38) prior to pegloticase was 55,314 units, after pegloticase the monthly ESA dose (n=37) was 37,290 units. This difference was statistically significant and warrants further investigation.
You Might Also Like
- Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout
- Pharmacokinetics May Be Factor in Success of Pegloticase Therapy for Gout
- Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Explore This IssueJune 2021
Also By This Author
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
- U.S. Food & Drug Administration. Center for drug evaluation and research summary review: Application 125293. 2010 Sep 14.
- Bleyer AJ, Zhang Y, Kshirsagar, et al. Pegloticase therapy in gout patients undergoing dialysis: a USRDS database study [abstract 183]. 2021 Apr.